



European Center of Pharmaceutical Medicine

Frontiers in Drug Development

## **BIOMARKERS IN DRUG DEVELOPMENT**

**PHARMACENTER  
UNIVERSITY OF BASEL**

**THURSDAY, FEBRUARY 9, 2012  
08:30 - 17:40**

Under the auspices of EUCOR  
European Confederation of the Upper Rhine Universities  
Basel, Freiburg i.Br., Strasbourg

Accredited by SwAPP/SGPM

**ADVANCED STUDIES**  
UNIVERSITÄT BASEL



## INTRODUCTION

A biomarker, or biological marker, is a substance or an event used as an indicator of a biological or disease state. Biomarkers play a crucial role in understanding the development of a particular human disease, the relationship between exposure and outcome and the identification of specific subpopulations at increased risk for a disease. They represent molecular or cellular key elements and can be used as a tracer to link a health outcome or a treatment effect to a therapeutic intervention.

The usage of biomarkers has changed research and development of new medicines. A great progress has been made in the discovery and validation of cutting-edge biomarkers in order to optimise the drug development process. But therapeutic relevant variations in the human biology that are identified as biomarkers are often uncovered during the later stage of the drug development process. Often, biomarkers are identified once several responses have been detected and a bedside-to-bench and back-to-bedside strategy can be assessed. The aim is to relate biomarkers with drugs, targets and genes to provide clinicians with a new opportunity to treat their patients individually, to improve cost efficiency, predict and minimise risk and avoid late stage attrition.

However, concerns on efficacy, cost and drug safety have encouraged the need for personalised medicine. Hence, biomarkers are approaching a personalised care translating in better health and resource allocation of health care budgets. In this seminar we will discuss the development and regulatory acceptance of classical and new biomarkers in drug development. The teaching faculty includes researchers, clinicians and governmental bodies.

We are looking forward to welcoming you and your colleagues to this seminar.



Prof. Thomas D. Szucs  
Director ECPM



Dr. Annette Mollet  
Head of Education & Training ECPM

## **MORNING: 08:30 – 12:10**

Chairperson: Alain J. van Gool, Leiden

Welcome

*Thomas D. Szucs, Basel*

Disease Targets and Biomarkers

*Nikolaus Wick, Tucson, AZ*

Designs for Cancer Biomarker Validation

*Mark Eccleston, Wilburton*

From Biomarker Strategies to Biomarker Activities and Back:  
Translating Clinical Biomarkers into Clinical Decisions

*Alain J. van Gool, Leiden*

Integrating Biomarker Studies in Early Phase Clinical Trials:  
Benefits and Challenges

*Adam Cohen, Leiden*

## **AFTERNOON: 13:10 – 17:40**

Biomarker-Driven Treatment Decisions and the Future of Pathology

*Manfred Dietel, Berlin*

Towards a Paradigm Shift in the Management of Cancer Therapy

*Arne Engelsberg, Berlin*

Biomarkers' Development and Usage: Satisfying Pre- and Post-Approval  
Regulatory Requirements in Europe

*Alasdair Breckenridge, London*

Biomarkers and Imaging

*Speaker invited*

## ORGANISER

ECPM, Institute of Pharmaceutical Medicine  
University of Basel  
Klingelbergstrasse 61, CH-4056 Basel, Switzerland  
Phone +41 61 265 7650  
Fax +41 61 265 7655  
E-mail [ecpm@unibas.ch](mailto:ecpm@unibas.ch)

## REGISTRATION

Via our homepage [www.ecpm.ch](http://www.ecpm.ch).  
Deadline: January 23, 2012

## REGISTRATION FEE

CHF 650.–  
CHF 550.– for ECPM Alumni and SwAPP / SGPM members.  
CHF 200.– for employees of universities and other non-commercial institutions.  
The fee includes meeting materials, lunch, coffee. Please transfer the registration fee to Vereinigtes Universitäts-Vermögen, Universität Basel, Petersplatz 1, Postfach 732, CH-4003 Basel, Basler Kantonalbank. Spiegelgasse, CH-4002 Basel, Bank Code Number: 770, Account Number: 16.550.470.91, SWIFT: BKBBCHBB, IBAN: CH2900770016055047091  
Please indicate your name.

**Cancellation:** Refund of fees, less 30% administrative charges will be given if cancellations are received in writing by January 23, 2012. After this date no refund can be given for cancellations.

## COURSE VENUE

Pharmacenter  
University of Basel  
Klingelbergstrasse 50, Basel, Switzerland

Bus to «Bernoullianum» from:  
Railway station SBB and SNCF: No. 30  
Railway station Badischer Bahnhof: No. 33  
Airport Basel-Mulhouse: No. 50 change at railway station SBB to No. 30  
Walking distance from Marktplatz (center): 15 minutes